Results per Page:
Fred Hutch researchers receive prestigious R01 research grants
NIH-funded awards will support multi-year investigations in HIV care and biostatistics
Virologist and HIV expert Dr. Michael Emerman retires
Emerman considers mentorship his most important duty in science
‘Action and progress link our globe’
HVTN’s Dr. Daniel Driffin focused on hope in remarks at White House World AIDS Day event
Laying the groundwork for a new cancer-preventive vaccine
Fred Hutch scientists garner large NCI award to uncover secrets of immune response to virus behind Kaposi sarcoma
First in-human HIV vaccine to induce virus-specific neutralizing antibodies
From the McElrath Lab, Vaccine and Infectious Disease and Clinical Research Divisions
Vaccine trial volunteer works to empower her community, end HIV
Community Advisory Board member Tasia Baldwin helps raise awareness of the ongoing HIV epidemic and how individuals can get involved in research aimed at ending it
Zeroing in on vaginal microbes that most increase HIV risk
Signature combination of BV bacteria and immune proteins associated with highest risk could help guide prevention
El momento en que se administra la TAR para el VIH es más importante de lo que imaginábamos
De los grupos de los doctores Edlefsen y Frenkel, Consorcio Oncológico
Timing of ART administration for HIV is more important than we thought
From the Edlefsen and Frenkel Groups, Cancer Consortium
Targeting B cells – a new approach to HIV treatment?
From the Peterson lab, Translational Science and Therapeutics Division
Using mathematical models to tell time of initial HIV infection in infants
From the Overbaugh/Lehman Lab, Cancer Consortium and Human Biology Division
Revolutionizing HIV Prevention: The Impact of Self-Testing Kits in Kenyan Pharmacies
From the Ortblad research group, Public Health Sciences Division
Obstáculos relacionados con la interseccionalidad para la atención médica del VIH y las ITS en las comunidades transgénero y no binaria del estado de Washington
Del Comité Asesor de Salud Sexual Trans y No Binaria de Seattle (STARS por sus siglas en inglés) y del Grupo Duerr de Resultados, Prevención y Epidemiología del VIH (HOPE por sus siglas en inglés)
Intersectional barriers to HIV/STI healthcare among Washington State transgender and nonbinary communities
From the Seattle Trans and Non-binary Sexual Health (STARS) Advisory Board and the Duerr HIV Outcomes, Prevention and Epidemiology (HOPE) Group
Finding the golden ticket? Cyclin T1 is required for HIV-1 latency reactivation
From the Emerman lab, Human Biology and Basic Sciences Divisions
How we measure success matters when evaluating HIV therapies
From Dr. Dan Reeves, Vaccine and Infectious Disease Division
Trimming the unknowns: identifying the function of primate TRIM34
From the Ohainle and Emerman labs, Human Biology and Basic Sciences Divisions
Expanding the delivery of HIV pre-exposure prophylaxis (PrEP) in Kenya
From the Ortblad Lab, Public Health Sciences Division
Panning for gold in a dependent-sea of genes
From the Emerman Lab, Human Biology and Basic Sciences Divisions